Michele Kosh

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.7K citations · Full text

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

Ajai Chari, Paula Rodríguez‐Otero, Helen O. McCarthy et al. · British Journal of Haematology · 2020 · 60 citations · Full text

A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule

María Jesús Cancelo Hidalgo, M.T. Martín Gómez, Nancy Lewis et al. · Journal of Clinical Oncology · 2008 · 47 citations

Immunology, Immunotherapeutics, Cancer Biology +18

Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors

IE Krop, Michele Kosh, Ivy Fearen et al. · Journal of Clinical Oncology · 2006 · 39 citations

Breast Oncology, Immunology, Pathology +20

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Haematology · 2023 · 35 citations

Hematological Malignancy, Subcutaneous Daratumumab, Medicine +8